Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Symptoms and Open Label Haloperidol in Cannabinoid Hyperemesis Syndrome (HALO)

NCT04176055 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT04176055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Symptoms and Open Label Haloperidol in Cannabinoid Hyperemesis Syndrome (HALO)
Lead sponsor
University of Calgary
Phase
Phase 4
Overall status
Completed
Start date
October 13, 2020
Completion date
June 1, 2022
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis hyperemesis syndrome